OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LNA59

LNA Sante SA

Healthcare Facilities & ServicesVerified

LNA Sante SA maintains a debt-to-equity ratio of 2.75, indicating a capital structure heavily reliant on debt financing. The company’s liquidity position is moderate, with a current ratio of 0.91, suggesting limited short-term liquidity to cover immediate liabilities. Free cash flow of EUR 97.7 million supports operational flexibility, but net cash is negative after subtracting total debt, signaling potential refinancing risks. Profitability metrics show a return on equity (ROE) of 7.31% and a return on assets (ROA) of 1.51%, both below the typical thresholds for high-margin healthcare services. Operating income of EUR 68.74 million represents a 7.53% margin on revenue, which is lower than the median for the Healthcare Facilities & Services industry. Gross profit of EUR 800.995 million reflects a 87.75% margin, indicating strong cost control in service delivery. The company operates through multiple subsidiaries across France and Belgium, with no disclosed segment breakdown. Revenue concentration is not explicitly stated, but the geographic split between France and Belgium suggests moderate diversification. Real estate operations are mentioned but not quantified, limiting visibility into their contribution to overall performance. Growth trajectory is not explicitly outlined in the financial snapshot, but the company’s operating cash flow of EUR 99.42 million and free cash flow of EUR 97.71 million suggest capacity for reinvestment or debt reduction. Capital expenditures of EUR -13.04 million indicate minimal recent investment in new facilities or technology. Risk factors include a high debt load and moderate liquidity, with a debt-to-equity ratio of 2.75 and a current ratio of 0.91. Dilution risk is assessed as low, with no near-term pressure from share issuance. Analysts have issued a mean recommendation of 1.60, indicating a generally positive outlook, though the company’s financial leverage remains a concern. Recent events include the company’s rebranding from Le Noble Age SA to LNA Sante SA, reflecting a strategic shift toward healthcare services. No recent filings or transcripts are provided, but the company’s operational focus on elderly care and real estate suggests ongoing alignment with demographic and regulatory trends in the healthcare sector.

30-day price · LNA(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyLNA Sante SA
TickerLNA.PA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. LNA Sante SA operates and manages comprehensive care establishments for dependent elderly people in France and Belgium, generating revenue through residential care services and real estate operations.

Classification. LNA Sante SA is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

LNA Sante SA maintains a debt-to-equity ratio of 2.75, indicating a capital structure heavily reliant on debt financing. The company’s liquidity position is moderate, with a current ratio of 0.91, suggesting limited short-term liquidity to cover immediate liabilities. Free cash flow of EUR 97.7 million supports operational flexibility, but net cash is negative after subtracting total debt, signaling potential refinancing risks. Profitability metrics show a return on equity (ROE) of 7.31% and a return on assets (ROA) of 1.51%, both below the typical thresholds for high-margin healthcare services. Operating income of EUR 68.74 million represents a 7.53% margin on revenue, which is lower than the median for the Healthcare Facilities & Services industry. Gross profit of EUR 800.995 million reflects a 87.75% margin, indicating strong cost control in service delivery. The company operates through multiple subsidiaries across France and Belgium, with no disclosed segment breakdown. Revenue concentration is not explicitly stated, but the geographic split between France and Belgium suggests moderate diversification. Real estate operations are mentioned but not quantified, limiting visibility into their contribution to overall performance. Growth trajectory is not explicitly outlined in the financial snapshot, but the company’s operating cash flow of EUR 99.42 million and free cash flow of EUR 97.71 million suggest capacity for reinvestment or debt reduction. Capital expenditures of EUR -13.04 million indicate minimal recent investment in new facilities or technology. Risk factors include a high debt load and moderate liquidity, with a debt-to-equity ratio of 2.75 and a current ratio of 0.91. Dilution risk is assessed as low, with no near-term pressure from share issuance. Analysts have issued a mean recommendation of 1.60, indicating a generally positive outlook, though the company’s financial leverage remains a concern. Recent events include the company’s rebranding from Le Noble Age SA to LNA Sante SA, reflecting a strategic shift toward healthcare services. No recent filings or transcripts are provided, but the company’s operational focus on elderly care and real estate suggests ongoing alignment with demographic and regulatory trends in the healthcare sector.
Key takeaways
  • LNA Sante SA operates in the Healthcare Facilities & Services industry with a focus on elderly care and real estate.
  • The company’s capital structure is heavily debt-dependent, with a debt-to-equity ratio of 2.75.
  • Profitability is moderate, with a ROE of 7.31% and a ROA of 1.51%.
  • Liquidity is constrained, with a current ratio of 0.91 and negative net cash after debt.
  • Analysts project a mean price target of EUR 32.25, with a generally positive recommendation.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$912.7M
Gross profit$801.0M
Operating income$68.7M
Net income$24.1M
R&D
SG&A
D&A
SBC
Operating cash flow$99.4M
CapEx-$13.0M
Free cash flow$97.7M
Total assets$1.60B
Total liabilities$1.27B
Total equity$330.3M
Cash & equivalents$94.8M
Long-term debt$907.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$330.3M
Net cash-$812.4M
Current ratio0.9
Debt/Equity2.8
ROA1.5%
ROE7.3%
Cash conversion4.1%
CapEx/Revenue-1.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricLNAActivity
Op margin7.5%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin2.6%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin87.8%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-1.4%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity275.0%71.3% medp25 60.7% · p75 71.3%top quartile
Observations
IR observations
Mean price target32.25 EUR
Median price target33.50 EUR
High price target35.00 EUR
Low price target27.00 EUR
Mean recommendation1.60 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.31 EUR
Last actual EPS2.13 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 09:56 UTC#44113e00
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 11:42 UTCJob: 40d82daf